Update on photodynamic therapy

Current Opinion in Ophthalmology

Volumn 11, Issue 3, 2000, Pages 166-170

  Regillo, Carl D ^a  

^a WILLS EYE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; DYE; LUTETIUM TEXAPHYRIN; PURPURIN; TIN ETHYL ETIOPURPURIN; UNCLASSIFIED DRUG;

ARTICLE; LASER COAGULATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME;

CHOROID; CHOROIDAL NEOVASCULARIZATION; HUMANS; MACULAR DEGENERATION; OPHTHALMIC SOLUTIONS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RETINA; TREATMENT OUTCOME;

EID: 0034129875     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-200006000-00002     Document Type: Article

References (19)

1. 1 O'Connell SR, Bressler NM: Age-related macular degeneration. In Vitreoretinal Disease: The Essentials. Edited by Regillo CD, Brown GC, Flynn HW New York: Thieme; 1999:213-240. A comprehensive, up-to-date, detailed review of AMD demographics, pathophysiology, diagnosis, and treatment.
2. 2 Fine SL: Photodynamic therapy with verteporfin is effective for selected patients with neovascular age-related macular degeneration [editorial]. Arch Ophthalmol 1999, 117:1400-1402. An excellent editorial that summarizes the current status of laser photocoagulation and PDT, along with other potentially useful treatment modalities.
3. 3 Donati G, Kapetanios AD, Pournaras CJ: Principles of treatment of choroidal neovascularization with photodynamic therapy in age-related macular degeneration. Semin Ophthalmol 1999, 14:2-10. A good review of PDT history, mechanism of action, and treatment principles.
4. 4 Liu H, Anderson RR: Photodynamic therapy in dermatology: recent developments. Dermatol Clin 1993, 11:1-13.
5. 5 Chambers RB, Arnson DS, Davidorf FH, et al.: Treatment of iris melanoma with dihematoporphyrin derivative distribution and long-term damage in rabbit ocular tissue. Cancer Res 1985, 45:1718-3725.
6. 6 Sery TW, Shields JA, Augsburger JJ, et al.: Photodynamic therapy of human ocular cancer. Ophthalmic Surg 1987, 18:413-418.
7. 7 Miller JW, Stinson WG, Gregory WA: Phthalocyanine photodynamic therapy of experimental iris neovascularization. Ophthalmology 1991, 98:1711-1719.
8. 8 Miller JW, Walsh AW, Kramer M, et al.: Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol 1995, 113:810-818.
9. 9 Schmidt-Erfurth U, Hasan T, Gragoudas E, et al.: Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 1994, 101:1953-1961.
10. 10 Kramer M, Miller JW, Michaud N, et al.: Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Ophthalmology 1996, 103:427-437.
11. 11 Allison BA, Waterfield E, Richter AM: The effects of plasma lipoproteins on in vitro tumor cell killing and in vivo tumor photosensitization with benzoporphyrin derivative. Photochem Photobiol 1991, 54:709-715.
12. 12 Husain D, Miller JW, Michaud N, et al. : Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol 1996, 114:978-985.
13. 13 Reinke MH, Canakis C, Husain D, et al.: Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. Ophthalmology 1999, 106:1915-1923.
14. 14 Miller JW, Schmidt-Erfurth U, Sickenberg M, et al.: Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 1999, 117:1161-1173. A detailed report that describes the initial phase I/II clinical experience with verteporfin for PDT. Optimum treatment parameters are delineated in this study.
15. 15 Schmidt-Erfurth U, Miller JW, Sickenberg M, et al.: Photodynamic ther7apy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol 1999, 117:1177-1187. A continuation of the verteporfin phase I/II clinical experience in which the safety and efficacy of retreatments are demonstrated.
16. 16 Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 1999, 117:1329-1345. The definitive phase III randomized clinical trial of PDT with verteporfin which proves that the treatment of mainly classic subfoveal neovascularization results in better visual outcomes (ie, less vision loss) than natural history.
17. 17 Peyman GA, Moshfeghi DM, Moshfeghi A, et al.: Photodynamic therapy for choriocapillaris using tin ethyl etiopurpurin (SnET2). Ophthalmic Surg Lasers 1997, 28:409-417.
18. 18 Moshfeghi DM, Gholam AP, Moshfeghi AA, et al.: Ocular vascular thrombosis following tin ethyl etiopurpurin (SnET2) photodynamic therapy: time dependencies. Ophthalmic Surg Lasers 1998, 29:663-668.
19. 19 Mori K, Yoneya S, Ohta M, et al.: Angiographic and histologic effects of fundus photodynamic therapy with a hydrophilic sensitizer (mono-1-aspartyl chlorin e6). Ophthalmology 1999, 106:1384-1391.